BioMarin, Huxley Pharmaceuticals deal

BioMarin acquired autoimmune company Huxley for $15 million up front. The deal gives BioMarin amifampridine which received a positive opinion from CHMP to treat Lambert-Eaton myasthenic syndrome (LEMS) in October. This is BioMarin's only autoimmune drug. Huxley stockholders are eligible for $7.5 million upon EC approval of the formulation of 3,4-diaminopyridine ( 3,4-DAP), a potassium channel blocker, and another $36 million in sales and U.S. development milestones. ...